Stay updated on Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2. This appears to be a minor software version update with no visible changes to the study information.SummaryDifference0.0%

- Check18 days agoChange DetectedRevision: v3.4.1 was added (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check19 days agoChange DetectedRevision: v3.4.1 appears on the page, replacing v3.4.0; there are no visible changes to trial content or details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check27 days agoChange DetectedShow glossary option added to the page interface. Minor text updates include capitalization changes to 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data,' and the revision version updated from v3.3.4 to v3.4.0.SummaryDifference0.2%

- Check34 days agoChange DetectedThe update timestamp label changes from 'Last Update Posted (Estimated)' to 'Last Update Posted' on the Study Details page.SummaryDifference0.0%

- Check41 days agoChange DetectedAdded a page revision note: 'Revision: v3.3.4' and removed 'Revision: v3.3.3' (metadata only; no impact on study details). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial page.